iOnctura Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$86.5M
- Investors
-
16
iOnctura General Information
Description
Developer of precision oral small molecule oncology therapies designed to treat neglected and hard-to-treat cancers. The company's bio-molecules include novel therapeutics that modulate key components of immunosuppression in the tumor microenvironment, enabling cancer patients to access more effective, less toxic treatments that extend healthspan.
Contact Information
Website
www.ionctura.comCorporate Office
- Campus Biotech
- Avenue Sécheron 15
- 1202 Genève
- Switzerland
Corporate Office
- Campus Biotech
- Avenue Sécheron 15
- 1202 Genève
- Switzerland
iOnctura Timeline
iOnctura Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series B) | 20-Jun-2024 | $86.5M | Completed | Clinical Trials - Phase 3 | ||
| 11. Later Stage VC | 27-Mar-2024 | Completed | Clinical Trials - Phase 3 | |||
| 10. Grant | 03-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 9. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 8. Later Stage VC | 20-Dec-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Grant | 05-Oct-2022 | Completed | Clinical Trials - Phase 1 | |||
| 6. Debt - General | 22-Sep-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A) | 14-Jul-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 20-Jun-2017 | $146K | $146K | Completed | Clinical Trials - Phase 1 | |
| 3. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
iOnctura Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
iOnctura Comparisons
Industry
Financing
Details
iOnctura Competitors (70)
One of iOnctura’s 70 competitors is TOLREMO therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TOLREMO therapeutics | Venture Capital-Backed | Basel, Switzerland | ||||
| T3 Pharmaceuticals | Formerly VC-backed | Allschwil, Switzerland | ||||
| Cellestia | Venture Capital-Backed | Basel, Switzerland | ||||
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| Anaveon | Venture Capital-Backed | Basel, Switzerland |
iOnctura Patents
iOnctura Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202508634-D0 | Combinations | Pending | 02-Jun-2025 | ||
| GB-202503115-D0 | Combinations | Pending | 04-Mar-2025 | ||
| WO-2026185333-A1 | Combinations comprising roginolisib | Pending | 04-Mar-2025 | ||
| GB-202418087-D0 | Biomarkers | Pending | 10-Dec-2024 | ||
| WO-2026125202-A1 | Biomarkers for treatment with phosphoinositide 3-kinase δ (pi3kδ) inhibitors | Pending | 10-Dec-2024 | C12Q1/6886 |
iOnctura Signals
iOnctura Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Syncona | Venture Capital | Minority | ||
| XGEN Venture | Impact Investing | Minority | ||
| Health ~ Holland | Government | Minority | ||
| KWF Kankerbestrijding | Corporation | Minority | ||
| European Innovation Council | Accelerator/Incubator | Minority |
iOnctura FAQs
-
When was iOnctura founded?
iOnctura was founded in 2017.
-
Where is iOnctura headquartered?
iOnctura is headquartered in Genève, Switzerland.
-
What is the size of iOnctura?
iOnctura has 34 total employees.
-
What industry is iOnctura in?
iOnctura’s primary industry is Drug Discovery.
-
Is iOnctura a private or public company?
iOnctura is a Private company.
-
What is iOnctura’s current revenue?
The current revenue for iOnctura is .
-
How much funding has iOnctura raised over time?
iOnctura has raised $144M.
-
Who are iOnctura’s investors?
Syncona, XGEN Venture, Health ~ Holland, KWF Kankerbestrijding, and European Innovation Council are 5 of 16 investors who have invested in iOnctura.
-
Who are iOnctura’s competitors?
TOLREMO therapeutics, T3 Pharmaceuticals, Cellestia, Meditope Biosciences, and Anaveon are some of the 70 competitors of iOnctura.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process